BetaVia Complete

CLINICAL Trial SHOWS BETAVIA Complete HELPS SUPPORT A HEALTHY IMMUNE SYSTEM*

Clinical trial results5 showed that active, healthy participants consuming BetaVia Complete experienced fewer upper respiratory tract infection (URTI) symptoms, sick days and symptom days over a 90-day supplementation period compared to a placebo. These findings were statistically significant. 

70% fewer upper respiratory tract infection symptoms
urti symptoms per participant, betavia versus placebo

Participants consuming BetaVia Complete reported 30 fewer symptoms over a 90-day supplementation period — that’s 70 percent fewer symptoms compared to a placebo.**

divider
3.3 fewer sick days
sick days per participant, betavia versus placebo

Over the 90-day supplementation period, participants consuming BetaVia Complete reported 3.3 fewer sick days compared to a placebo.

divider
10 fewer urti symptom days
sick days per participant, betavia versus placebo

Participants consuming BetaVia Complete experienced 10 fewer symptom days over the 90-day supplementation period, compared to those taking a placebo.  A symptom day is a day in which a participant experiences at least one URTI symptom.

divider

Want to learn more about the clinical trial? Contact us for additional information. 

*Recommended use: 375 mg/day of BetaVia Complete by healthy adults

**The data for URTI was collected using a validated survey WURSS -24 which surveys the following symptoms: runny nose, plugged nose, sneezing, sore throat, scratchy throat, cough, hoarseness, head congestion, chest congestion, feeling tired, headache, body aches and fever.

Ready to add BetaVia to your formulation?

Request more information below.

Download BetaVia™ Complete clinical trial infographic

Boosting Immunity with BetaVia™ Complete

These statements have not been evaluated by the US Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

The information on this webpage is a business-to-business information and not intended for the final consumer. Certain statements may not be applicable in all geographical regions. Product labeling and associated claims differs based upon government requirements and country or region specific information should also be considered when labeling or advertising to final consumers.

This web page and its associated brochures and other documents do not constitute or provide scientific or medical advice, diagnosis, or treatment and are distributed without warranty of any kind, either expressly or implied. This web page, its title or contents and associated brochures and other documents do not in any way make recommendations for health or marketing claims by the reader. Country and region specific regulations should be considered in this regard. Each claim or statement about the effectiveness of Kemin products and/or each claim or statement comparing the effectiveness of Kemin products to the effectiveness of other products is expressly limited to the United States, unless otherwise disclosed on the Kemin websites.

BetaVia References and Studies

References

  1. Patents granted a patent on beta 1,3 glucans for modulating immune function (US Patent 10,912,794).  This new patent joins a previously issued patent, US 9574217, on the production of immune modulation using algae from a proprietary strain of Euglena gracilis ATCC PTA-123017.
  2. Spiering, M. J. (2015). Primer on the Immune System. Alcohol research: current reviews, 37(2), 171–175
  3. KHTL-017-149 Characteristics and Prebiotic like Properties of BetaVia Complete
  4. KHTL-017-159  BetaVia Complete Supports Gut Health after Induced Colitis in Mice
  5. Evans, M., et al., Effect of a Euglena gracilis Fermentate on Immune Function in Healthy, Active Adults: A Randomized, Double-Blind, Placebo-Controlled Trial. Nutrients, 2019, 11(12), 2926